Our product candidate, eflornithine, is a novel cytostatic (growth inhibiting) agent, which we are developing for the potential treatment of patients with anaplastic astrocytoma (AA).
Eflornithine delays or freezes tumor growth by inhibiting production of the enzyme that can cause tumor growth in certain types of cancer.
The company’s lead product candidate under active development is eflornithine in an oral solution. Eflornithine is a novel cytostatic agent that inhibits tumor growth by preventing cell division and proliferation which Orbus Therapeutics is developing for the treatment of patients with anaplastic astrocytoma (AA), or Grade 3 glioma, a rare and deadly form of brain cancer. Eflornithine irreversibly blocks ornithine decarboxylase (ODC), a key enzyme associated with various types of cancer.
Orbus Therapeutics intends to develop and commercialize eflornithine in North America.